Multiple Sclerosis International最新文献_第5页

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. Copaxone®(醋酸格拉替默)治疗多发性硬化症20年后的持久临床价值

IF 2.5

Multiple Sclerosis International Pub Date : 2019-01-15 eCollection Date: 2019-01-01 DOI: 10.1155/2019/7151685

Daniel R Wynn

{"title":"Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use.","authors":"Daniel R Wynn","doi":"10.1155/2019/7151685","DOIUrl":"https://doi.org/10.1155/2019/7151685","url":null,"abstract":"Multiple sclerosis (MS) is a chronic progressive neurodegenerative demyelinating disease affecting the central nervous system. Glatiramer acetate (GA; Copaxone®) was the first disease-modifying treatment (DMT) for MS successfully tested in humans (1977) and was approved by the US Food and Drug Administration in December 1996. Since then, there have been numerous developments in the MS field: advances in neuroimaging allowing more rapid and accurate diagnosis; the availability of a range of DMTs including immunosuppressant monoclonal antibodies and oral agents; a more holistic approach to treatment by multidisciplinary teams; and an improved awareness of the need to consider a patient's preferences and patient-reported outcomes such as quality of life. The use of GA has endured throughout these advances. The purpose of this article is to provide an overview of the important developments in the MS field during the 20 years since GA was approved and to review clinical data for GA in MS, with the aim of understanding the continued and widespread use of GA. Both drug-related (efficacy versus side-effect profile and monitoring requirements) and patient factors (preferences regarding mode of administration and possible pregnancy) will be explored.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2019 ","pages":"7151685"},"PeriodicalIF":2.5,"publicationDate":"2019-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/7151685","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses. 抗髓磷脂少突胶质细胞糖蛋白和人白细胞抗原作为儿童和青少年多发性硬化症的标志物:诊断、临床表型和治疗反应。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-11-22 eCollection Date: 2018-01-01 DOI: 10.1155/2018/8487471

Maria P Gontika, Maria C Anagnostouli

{"title":"Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses.","authors":"Maria P Gontika, Maria C Anagnostouli","doi":"10.1155/2018/8487471","DOIUrl":"https://doi.org/10.1155/2018/8487471","url":null,"abstract":"Early-onset (pediatric and adolescent) multiple sclerosis (MS) is a well-established demyelinating disease that accounts for approximately 3-5% of all MS cases. Thus, identifying potential biomarkers that can reflect the pathogenic mechanisms, disease course and prognosis, and therapeutic response in such patients is of paramount importance. Myelin oligodendrocyte glycoprotein (MOG) has been regarded as a putative autoantigen and autoantibody target in patients with demyelinating diseases for almost three decades. However, recent studies have suggested that antibodies against MOG represent a distinct clinical entity of dominantly humoral profile, with a range of clinical phenotypes closely related to the age of onset, specific patterns of disease course, and responses to treatment. Furthermore, the major histocompatibility complex (MHC)-which has been regarded as the \"gold standard\" for attributing genetic burden in adult MS since the early 1970s-has also emerged as the primary genetic locus in early-onset MS, particularly with regard to the human leukocyte antigen (HLA) alleles DRB1⁎1501 and DRB1⁎0401. Recent studies have investigated the potential interactions among HLA, MOG, and environmental factors, demonstrating that early-onset MS is characterized by genetic, immunogenetic, immunological, and familial trait correlations. In this paper, we review recent evidence regarding HLA-genotyping and MOG antibodies-the two most important candidate biomarkers for early-onset MS-as well as their potential application in the diagnosis and treatment of MS.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"8487471"},"PeriodicalIF":2.5,"publicationDate":"2018-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/8487471","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36866851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT. 参与者对服用褪黑素治疗多发性硬化夜尿症的看法是什么?一项双盲随机对照试验的定性研究。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-10-18 eCollection Date: 2018-01-01 DOI: 10.1155/2018/4721505

Rafiyah Khan, Alan Uren, Luke Canham, David Cottrell, Marcus J Drake, Nikki Cotterill

{"title":"What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT.","authors":"Rafiyah Khan, Alan Uren, Luke Canham, David Cottrell, Marcus J Drake, Nikki Cotterill","doi":"10.1155/2018/4721505","DOIUrl":"https://doi.org/10.1155/2018/4721505","url":null,"abstract":"Background: Multiple Sclerosis (MS) is a chronic neurological disorder caused by neurodegeneration within the central nervous system. It results in impaired physical, cognitive, and psychological functioning and can also lead to lower urinary tract symptoms including nocturia. While clinical trials have suggested an association between nocturia and melatonin secretion, to our knowledge, no qualitative research has been conducted on the experience of taking melatonin to treat nocturia in progressive MS within a clinical trial.Methods: 17 semistructured qualitative interviews were conducted as part of a double-blind, randomised, placebo controlled, crossover, clinical trial with consenting adults with MS. Interviews explored participants' experiences of nocturia associated with MS and their experience of taking melatonin as a trial treatment for nocturia versus a placebo. Data was analysed using a thematic analysis.Results: Themes on the experience of nocturia revealed participants' understandings of nocturia, the impact it had on their night, and increased daily fatigue. Themes on the intervention showed perceived improvements to nocturia, sleep, and energy and negative effects including lethargy, a lack of significant change, and physical side effects including vivid dreams.Conclusion: This qualitative exploration revealed an association between nocturia and increased levels of fatigue during the day by those with MS. However, perspectives towards the effectiveness of melatonin as a potential treatment varied as both placebo and melatonin were perceived as having very similar effects.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"4721505"},"PeriodicalIF":2.5,"publicationDate":"2018-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4721505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36716729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The Role of Wearable Devices in Multiple Sclerosis. 可穿戴设备在多发性硬化症中的作用。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-10-10 DOI: 10.1155/2018/7627643

Maddalena Sparaco, Luigi Lavorgna, Renata Conforti, Gioacchino Tedeschi, Simona Bonavita

{"title":"The Role of Wearable Devices in Multiple Sclerosis.","authors":"Maddalena Sparaco, Luigi Lavorgna, Renata Conforti, Gioacchino Tedeschi, Simona Bonavita","doi":"10.1155/2018/7627643","DOIUrl":"10.1155/2018/7627643","url":null,"abstract":"Multiple sclerosis (MS) is the most common neurological disorder in young adults. The prevalence of walking impairment in people with MS (pwMS) is estimated between 41% and 75%. To evaluate the walking capacity in pwMS, the patient reported outcomes (PROs) and performance-based tests (i.e., the 2-minute walk test, the 6-minute walk test, the Timed 25-Foot Walk Test, the Timed Up and Go Test, and the Six Spot Step Test) could be used. However, some studies point out that the results of both performance-based tests and objective measures (i.e., by accelerometer) could not reflect patient reports of walking performance and impact of MS on daily life. This review analyses different motion sensors embedded in smartphones and motion wearable device (MWD) that can be useful to measure free-living walking behavior, to evaluate falls, fatigue, sedentary lifestyle, exercise, and quality of sleep in everyday life of pwMS. Caveats and limitations of MWD such as variable accuracy, user adherence, power consumption and recharging, noise susceptibility, and data management are discussed as well.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"7627643"},"PeriodicalIF":2.5,"publicationDate":"2018-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/7627643","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36657906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire. 估计多发性硬化症患者的日常神经心理功能:希腊多发性硬化症神经心理问卷的信度和效度。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-09-25 eCollection Date: 2018-01-01 DOI: 10.1155/2018/6301535

Eleni Konstantinopoulou, Panagiotis Ioannidis, Christos Bakirtzis, Virginia Giantzi, Theodora Afrantou, Dimitrios Parissis, Lambros Messinis, Grigorios Nasios, Nikolaos Grigoriadis

{"title":"Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire.","authors":"Eleni Konstantinopoulou, Panagiotis Ioannidis, Christos Bakirtzis, Virginia Giantzi, Theodora Afrantou, Dimitrios Parissis, Lambros Messinis, Grigorios Nasios, Nikolaos Grigoriadis","doi":"10.1155/2018/6301535","DOIUrl":"https://doi.org/10.1155/2018/6301535","url":null,"abstract":"The Multiple Sclerosis Neuropsychological Questionnaire is a brief screening questionnaire for the assessment of everyday neuropsychological competence of patients with Multiple Sclerosis. The aim of the present study was to examine psychometric properties of the Greek version of the instrument. One hundred and three MS patients and 60 informants participated in the present study and completed the questionnaire. From the initial patient sample, 51 participants completed broadly used neuropsychological tests and measures estimating cognitive failures and depression. Moreover, after a six-month interval the MSNQ was administered to 58 patients from the initial sample in order to explore test-retest reliability. Cronbach's α was 0.92 and 0.93 for patient and informant forms, respectively. The patient form was correlated significantly with measures of cognitive failures and depression. Low correlations were found between the informant form and performance on cognitive tests. In regard to the patient form, significant correlation was observed between repeated administrations and, psychometrically, the three-factor structure was preferable than the one-factor structure. The present study confirms the already established pattern of correlations among the two MSNQ forms, neuropsychological test performance and depression measurements. Additional research is needed in order to define a cut-off score for the MSNQ-I providing further information about the diagnostic interpretability of the instrument.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"6301535"},"PeriodicalIF":2.5,"publicationDate":"2018-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/6301535","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36658775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Decision-Making in Multiple Sclerosis Patients: A Systematic Review. 多发性硬化症患者的决策:一项系统综述。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-03-12 eCollection Date: 2018-01-01 DOI: 10.1155/2018/7835952

Mireille Neuhaus, Pasquale Calabrese, Jean-Marie Annoni

{"title":"Decision-Making in Multiple Sclerosis Patients: A Systematic Review.","authors":"Mireille Neuhaus, Pasquale Calabrese, Jean-Marie Annoni","doi":"10.1155/2018/7835952","DOIUrl":"https://doi.org/10.1155/2018/7835952","url":null,"abstract":"Background: Multiple sclerosis (MS) is frequently associated with cognitive and behavioural deficits. A growing number of studies suggest an impact of MS on decision-making abilities. The aim of this systematic review was to assess if (1) performance of MS patients in decision-making tasks was consistently different from controls and (2) whether this modification was associated with cognitive dysfunction and emotional alterations.Methods: The search was conducted on Pubmed/Medline database. 12 studies evaluating the difference between MS patients and healthy controls using validated decision-making tasks were included. Outcomes considered were quantitative (net scores) and qualitative measurements (deliberation time and learning from feedback).Results: Quantitative and qualitative decision-making impairment in MS was present in 64.7% of measurements. Patients were equally impaired in tasks for decision-making under risk and ambiguity. A correlation to other cognitive functions was present in 50% of cases, with the highest associations in the domains of processing speed and attentional capacity.Conclusions: In MS patients, qualitative and quantitative modifications may be present in any kind of decision-making task and can appear independently of other cognitive measures. Since decision-making abilities have a significant impact on everyday life, this cognitive aspect has an influential importance in various MS-related treatment settings.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"7835952"},"PeriodicalIF":2.5,"publicationDate":"2018-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/7835952","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36065096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka. 斯里兰卡多发性硬化症患者鞘内抗体反应明显低。

IF 2.5

Multiple Sclerosis International Pub Date : 2018-02-28 eCollection Date: 2018-01-01 DOI: 10.1155/2018/5342936

S M K Gamage, I Wijeweera, S B Adikari, Katharina Fink, Jan Hillert, Anna Fogdell-Hahn, H M A Sominanda

{"title":"Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.","authors":"S M K Gamage, I Wijeweera, S B Adikari, Katharina Fink, Jan Hillert, Anna Fogdell-Hahn, H M A Sominanda","doi":"10.1155/2018/5342936","DOIUrl":"https://doi.org/10.1155/2018/5342936","url":null,"abstract":"Multiple sclerosis (MS) is a heterogeneous disease which is poorly studied in Asia, where the disease is known to be rare with significant differences in clinical and radiological presentations and intrathecal antibody response. Therefore the objective of this study was to determine clinical presentation, radiological and neurophysiological characteristics, and oligoclonal band status in Sri Lankan MS patients, following careful exclusion of patients with neuromyelitis optica spectrum disorders and other conditions mimicking multiple sclerosis. Sixty-nine MS patients were recruited to the study adhering to McDonald 2010 criteria. Their clinical presentation, characteristics of central nervous system lesions in magnetic resonance imaging, visual evoked potential (VEP) results, oligoclonal bands (OCB), and AQP4 antibody status were studied. Of 69 MS patients, 54%, 6%, and 1% were relapsing remitting, secondary progressive, and primary progressive, respectively, and 39% were patients with clinically isolated syndrome. The commonest clinical presentations were cerebral motor followed by cerebral sensory and optic neuritis. Majority had typical periventricular and infratentorial lesions in MRI. Though not clinically apparent, bilateral delay of P100 wave latency was present in 52%. OCB positivity was 42% and AQP4 antibody was positive in only one patient. In conclusion, this group of Sri Lankan MS patients shares most of the clinical and radiological features of Caucasian MS patients. However, the OCB positivity is lower in this group, when compared to the Caucasian MS populations.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2018 ","pages":"5342936"},"PeriodicalIF":2.5,"publicationDate":"2018-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/5342936","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36034293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis 抗水通道蛋白4抗体在马来西亚一家三级医院的特发性炎性脱髓鞘疾病患者中的流行:表现和预后

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-19 DOI: 10.1155/2017/1359761

S. Abdullah, W. Wong, C. Tan

{"title":"The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis","authors":"S. Abdullah, W. Wong, C. Tan","doi":"10.1155/2017/1359761","DOIUrl":"https://doi.org/10.1155/2017/1359761","url":null,"abstract":"Background. There have been inconsistent reports on the prevalence and pathogenicity of anti-Aquaporin 4 (AQP4) in patients presented with idiopathic inflammatory demyelinating diseases (IIDDs). Objective. To estimate the prevalence of anti-AQP4 antibody in patients with IIDDs presented to University Malaya Medical Centre in terms of patients' clinical and radiological presentations and prognoses. Methods. Retrospective data review of IIDDs patients presented from 2005 to 2015. Patients were classified into classical multiple sclerosis (CMS), opticospinal (OS) presentation, optic neuritis (ON), transverse myelitis (TM), brainstem syndrome (BS), and tumefactive MS. Anti-Aquaporin 4 antibody was tested using the Indirect Immunofluorescence Test (IIFT) cell-based assay. Statistical analysis was done using the SPSS version 20. Results. Anti-AQP4 antibody was detected in 53% of patients presented with IIDDs. CMS was more common in the seronegative group, 27/47 (57.45%; p < 0.001). Conversely, OS involvement was more common in the seropositive group, 26/53 (49.06%; p < 0.001). Longitudinally extensive spinal cord lesions (LESCLs) on MRI were also more common in the seropositive group, 29/40 (72.50%; p = 0.004). Only 2/40 (5.00%) had MRI evidence of patchy or multiple short-segment spinal cord lesions in the AQP4-positive group (p = 0.003). The relapse rate and Expanded Disability Status Scale (EDSS) were also higher in the seropositive group (5.43 versus 3.17, p = 0.005; 4.07 versus 2.51, p = 0.006, resp.). Typical clinical presentations that defined NMO were also seen in the seronegative patients, but in a lower frequency. Conclusion. Our cohort of patients had a higher prevalence of seropositivity of anti-AQP4 antibody as compared to those in Western countries. This was also associated with a more typical presentation of opticospinal involvement with LESCLs on MRI, a higher rate of relapse, and EDSS.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2017-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/1359761","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43353621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Which Environmental Factor Is Correlated with Long-Term Multiple Sclerosis Incidence Trends: Ultraviolet B Radiation or Geomagnetic Disturbances? 哪种环境因素与多发性硬化症的长期发病趋势相关:紫外线B辐射还是地磁干扰?

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-01 Epub Date: 2017-10-24 DOI: 10.1155/2017/4960386

Seyed Aidin Sajedi, Fahimeh Abdollahi

{"title":"Which Environmental Factor Is Correlated with Long-Term Multiple Sclerosis Incidence Trends: Ultraviolet B Radiation or Geomagnetic Disturbances?","authors":"Seyed Aidin Sajedi, Fahimeh Abdollahi","doi":"10.1155/2017/4960386","DOIUrl":"https://doi.org/10.1155/2017/4960386","url":null,"abstract":"Background: Insufficient received ultraviolet B radiation (UV) is regarded as the main environmental risk factor (RF) for MS in vitamin D deficiency hypothesis. Nevertheless, geomagnetic disturbance (GMD) has also been proposed as a potential trigger for MS in GMD hypothesis. The aim of this study was to investigate which of these mentioned RF is correlated with long-term ultradecadal MS incidence.Methods: After a systematic search, long-term incidence reports of the United Kingdom (UK), Denmark, Tayside County, Nordland County, the Orkney, and Shetland Islands were selected for this retrospective time-series study. Possible lead-lag relationships between MS incidence, GMD, and UV were evaluated by cross-correlation analysis.Results: Significant positive correlations between GMD and MS incidence were seen in Tayside County (at lag of 2 years: rS = 0.38), Denmark (peak correlation at lag of 2 years: rS = 0.53), and UK (at lag of 1 year: rS = 0.50). We found a positive correlation between received UV and MS incidences in the Nordland at lag of 1 year (rS = 0.49).Conclusion: This study found significant positive correlations between alterations in GMD with alterations in long-term MS incidence in three out of six studied locations and supports the GMD hypothesis. The observed significant correlation between MS and UV is positive; hence it is not supportive for UV related vitamin D deficiency hypothesis.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 ","pages":"4960386"},"PeriodicalIF":2.5,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4960386","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35219389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Dealing with Chronic Illness: Experiences of Iranian Families of Persons with Multiple Sclerosis-A Qualitative Study. 处理慢性疾病:伊朗多发性硬化症患者家庭的经验-定性研究。

IF 2.5

Multiple Sclerosis International Pub Date : 2017-01-01 Epub Date: 2017-09-07 DOI: 10.1155/2017/9243161

Hossein Ebrahimi, Hadi Hasankhani, Hossein Namdar, Esmail Khodadadi, Marjaneh Fooladi

{"title":"Dealing with Chronic Illness: Experiences of Iranian Families of Persons with Multiple Sclerosis-A Qualitative Study.","authors":"Hossein Ebrahimi, Hadi Hasankhani, Hossein Namdar, Esmail Khodadadi, Marjaneh Fooladi","doi":"10.1155/2017/9243161","DOIUrl":"https://doi.org/10.1155/2017/9243161","url":null,"abstract":"Background: Today family members are providing care and support to each other during illness. In particular, in chronic illness, such as multiple sclerosis, the families are more involved in caring for and supporting their patients, so they use several strategies to cope with this situation. The purpose of this study was to explore the coping strategies in family caregivers of persons with multiple sclerosis in Iran.Methods: This is a qualitative study that was conducted through 18 family caregivers of persons with multiple sclerosis. A purposeful sampling method was used. Data were collected through semistructured and in-depth interviews conducted in Multiple Sclerosis Society and hospitals of Tabriz in Iran. The collected data was analyzed according to qualitative content analysis.Results: Five main categories were elicited from interviews: \"using spirituality,\" \"living with hope,\" \"experiencing persistence and stability,\" \"seeking support,\" and \"seeking alternative treatments.\" Conclusion. The study findings can help to inform the support given to families to help them cope with the effects of caring for someone with multiple sclerosis. Health system managers and professionals by using these results are able to support patients and their families appropriately in order to improve their quality of life and alleviate the complications of disease.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2017 ","pages":"9243161"},"PeriodicalIF":2.5,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/9243161","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35503490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14